NO20004045L - 2-(purin-9-yl)-tetrahydrofuran-3,4-diolderivater - Google Patents

2-(purin-9-yl)-tetrahydrofuran-3,4-diolderivater

Info

Publication number: NO20004045L
Authority: NO; Norway
Prior art keywords: purin; tetrahydrofuran; diol derivative; diol; derivative
Prior art date: 1998-02-14

Application number

NO20004045A

Other languages

English (en)

Norwegian (no)

Other versions

NO20004045D0 (no

Inventor

Chuen Chan

Caroline Mary Cook

Richard Peter Charles Cousins

Brian Cox

Frank Ellis

Stephen Swanson

David Edmund Bays

Hazel Joan Dyke

Joanna Victoria Geden

Original Assignee

Glaxo Group Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-02-14

Filing date

2000-08-11

Publication date

2000-08-11

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26313119&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20004045(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1998-02-14 Priority claimed from GBGB9803169.3A external-priority patent/GB9803169D0/en

1998-06-23 Priority claimed from GBGB9813533.8A external-priority patent/GB9813533D0/en

2000-08-11 Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd

2000-08-11 Publication of NO20004045L publication Critical patent/NO20004045L/no

2000-08-11 Publication of NO20004045D0 publication Critical patent/NO20004045D0/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Hospice & Palliative Care (AREA)
Psychiatry (AREA)
Rheumatology (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

NO20004045A 1998-02-14 2000-08-11 2-(purin-9-yl)-tetrahydrofuran-3,4-diolderivater NO20004045D0 (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
GBGB9803169.3A GB9803169D0 (en)	1998-02-14	1998-02-14	Chemical compounds
GBGB9813533.8A GB9813533D0 (en)	1998-06-23	1998-06-23	Chemical compounds
PCT/EP1999/000915 WO1999041267A1 (fr)	1998-02-14	1999-02-12	Derives de 2-(purine-9-yl) -tetrahydrofuranne-3, 4-diol

Publications (2)

Publication Number	Publication Date
NO20004045L true NO20004045L (no)	2000-08-11
NO20004045D0 NO20004045D0 (no)	2000-08-11

Family

ID=26313119

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20004045A NO20004045D0 (no)	1998-02-14	2000-08-11	2-(purin-9-yl)-tetrahydrofuran-3,4-diolderivater

Country Status (31)

Country	Link
US (1)	US6610665B1 (fr)
EP (1)	EP1056759B1 (fr)
JP (1)	JP2002503669A (fr)
KR (1)	KR20010082512A (fr)
AP (1)	AP2000001881A0 (fr)
AR (1)	AR017457A1 (fr)
AT (1)	ATE223429T1 (fr)
AU (1)	AU757156B2 (fr)
BR (1)	BR9907886A (fr)
CA (1)	CA2319009A1 (fr)
CO (1)	CO4990969A1 (fr)
DE (1)	DE69902758T2 (fr)
DK (1)	DK1056759T3 (fr)
EA (1)	EA200000759A1 (fr)
EE (1)	EE200000358A (fr)
ES (1)	ES2183516T3 (fr)
HR (1)	HRP20000538A2 (fr)
HU (1)	HUP0100702A3 (fr)
IL (1)	IL137402A0 (fr)
IS (1)	IS5576A (fr)
MA (1)	MA27121A1 (fr)
NO (1)	NO20004045D0 (fr)
NZ (1)	NZ505812A (fr)
PE (1)	PE20000270A1 (fr)
PL (1)	PL342396A1 (fr)
PT (1)	PT1056759E (fr)
SK (1)	SK12002000A3 (fr)
SV (1)	SV1999000016A (fr)
TR (1)	TR200002355T2 (fr)
WO (1)	WO1999041267A1 (fr)
YU (1)	YU50800A (fr)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6514949B1 (en)	1994-07-11	2003-02-04	University Of Virginia Patent Foundation	Method compositions for treating the inflammatory response
YU44900A (sh) *	1998-01-31	2003-01-31	Glaxo Group Limited	Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
CO4990969A1 (es) *	1998-02-14	2000-12-26	Glaxo Group Ltd	Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
CN1313861A (zh) *	1998-06-23	2001-09-19	葛兰素集团有限公司	2－(嘌呤－9－基)－四氢呋喃－3,4－二醇衍生物
GB9813554D0 (en)	1998-06-23	1998-08-19	Glaxo Group Ltd	Chemical compounds
GB9813565D0 (en) *	1998-06-23	1998-08-19	Glaxo Group Ltd	Chemical compounds
US7378400B2 (en)	1999-02-01	2008-05-27	University Of Virginia Patent Foundation	Method to reduce an inflammatory response from arthritis
US6232297B1 (en)	1999-02-01	2001-05-15	University Of Virginia Patent Foundation	Methods and compositions for treating inflammatory response
US7427606B2 (en)	1999-02-01	2008-09-23	University Of Virginia Patent Foundation	Method to reduce inflammatory response in transplanted tissue
GB9930075D0 (en) *	1999-12-20	2000-02-09	Glaxo Group Ltd	Medicaments
US7638496B2 (en)	2000-02-15	2009-12-29	Valeant Pharmaceuticals North America	Nucleoside analogs with carboxamidine modified monocyclic base
GB0022695D0 (en)	2000-09-15	2000-11-01	Pfizer Ltd	Purine Derivatives
GB0115178D0 (en) *	2001-06-20	2001-08-15	Glaxo Group Ltd	Compounds
JP4514452B2 (ja)	2001-10-01	2010-07-28	ユニバーシティオブバージニアパテントファウンデーション	Ａ２ａアゴニスト活性を有する２−プロピルアデノシン・アナログおよびその組成物
TW200519106A (en)	2003-05-02	2005-06-16	Novartis Ag	Organic compounds
US6930093B2 (en) *	2003-07-10	2005-08-16	Valeant Research & Development	Use of ribofuranose derivatives against inflammatory bowel diseases
GB0401334D0 (en)	2004-01-21	2004-02-25	Novartis Ag	Organic compounds
TWI346109B (en)	2004-04-30	2011-08-01	Otsuka Pharma Co Ltd	4-amino-5-cyanopyrimidine derivatives
GB0411056D0 (en)	2004-05-18	2004-06-23	Novartis Ag	Organic compounds
AR049384A1 (es)	2004-05-24	2006-07-26	Glaxo Group Ltd	Derivados de purina
US7442687B2 (en)	2004-08-02	2008-10-28	The University Of Virginia Patent Foundation	2-polycyclic propynyl adenosine analogs having A2A agonist activity
CA2576826C (fr)	2004-08-02	2014-09-30	University Of Virginia Patent Foundation	Analogues de 2-propynyle adenosine comprenant des groupes 5'-ribose modifies presentant une activite agoniste a<sb>2a</sb>
US7576069B2 (en)	2004-08-02	2009-08-18	University Of Virginia Patent Foundation	2-polycyclic propynyl adenosine analogs having A2A agonist activity
GB0424284D0 (en)	2004-11-02	2004-12-01	Novartis Ag	Organic compounds
GB0426164D0 (en)	2004-11-29	2004-12-29	Novartis Ag	Organic compounds
GB0510390D0 (en)	2005-05-20	2005-06-29	Novartis Ag	Organic compounds
GB0514809D0 (en)	2005-07-19	2005-08-24	Glaxo Group Ltd	Compounds
MY144906A (en)	2005-10-21	2011-11-30	Novartis Ag	Human antibodies against il13 and therapeutic uses
GB0601951D0 (en)	2006-01-31	2006-03-15	Novartis Ag	Organic compounds
BRPI0717564A2 (pt)	2006-09-29	2013-10-22	Novartis Ag	Pirazolopirimidinas como inibidores de pi3k lipídeo cinase
CA2667962A1 (fr)	2006-10-30	2008-05-08	Novartis Ag	Composes heterocycliques en tant qu'agents anti-inflammatoires
JP5584138B2 (ja)	2008-01-11	2014-09-03	ノバルティスアーゲー	キナーゼ阻害剤としてのピリミジン類
DK2391366T3 (da)	2009-01-29	2013-01-07	Novartis Ag	Substituerede benzimidazoler til behandling af astrocytomer
US8389526B2 (en)	2009-08-07	2013-03-05	Novartis Ag	3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
JP5781510B2 (ja)	2009-08-12	2015-09-24	ノバルティスアーゲー	ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
HRP20190016T1 (hr)	2009-08-17	2019-03-08	Intellikine, Llc	Heterociklički spojevi i njihova upotreba
MX2012002179A (es)	2009-08-20	2012-03-16	Novartis Ag	Compuestos heterociclicos de oxima.
UY33597A (es)	2010-09-09	2012-04-30	Irm Llc	Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (fr)	2010-09-09	2012-03-15	Irm Llc	Composés et compositions comme inhibiteurs de trk
US20130324526A1 (en)	2011-02-10	2013-12-05	Novartis Ag	[1,2,4] triazolo [4,3-b] pyridazine compounds as inhibitors of the c-met tyrosine kinase
JP5808826B2 (ja)	2011-02-23	2015-11-10	インテリカイン，エルエルシー	複素環化合物およびその使用
JP5959541B2 (ja)	2011-02-25	2016-08-02	ノバルティスアーゲー	Ｔｒｋ阻害剤としてのピラゾロ［１，５−ａ］ピリジン
WO2013038362A1 (fr)	2011-09-15	2013-03-21	Novartis Ag	3-(quinolin-6-ylthio)-[1,2,4]triazolo[4,3-a]pyradines substituées en position 6 à activité tyrosine kinase
JP6130391B2 (ja)	2011-11-23	2017-05-17	インテリカイン，エルエルシー	Ｍｔｏｒ阻害剤を使用する強化された治療レジメン
WO2013149581A1 (fr)	2012-04-03	2013-10-10	Novartis Ag	Produits combinés comprenant des inhibiteurs de tyrosine kinase et leur utilisation
HK1219421A1 (zh)	2013-03-15	2017-04-07	因特利凯有限责任公司	激酶抑制剂的组合及其用途
TW201605450A (zh)	2013-12-03	2016-02-16	諾華公司	Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
WO2016011658A1 (fr)	2014-07-25	2016-01-28	Novartis Ag	Polythérapie
BR112017001695A2 (pt)	2014-07-31	2017-11-21	Novartis Ag	terapia de combinação
TW202140550A (zh)	2020-01-29	2021-11-01	瑞士商諾華公司	使用抗ｔｓｌｐ抗體治療炎性或阻塞性氣道疾病之方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9414193D0 (en)	1994-07-14	1994-08-31	Glaxo Group Ltd	Compounds
TW528755B (en) *	1996-12-24	2003-04-21	Glaxo Group Ltd	2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
CO4990969A1 (es) *	1998-02-14	2000-12-26	Glaxo Group Ltd	Derivados de 2-(purin-9-il)-tetrahidrofuran-3,4-diol
CN1313861A (zh) *	1998-06-23	2001-09-19	葛兰素集团有限公司	2－(嘌呤－9－基)－四氢呋喃－3,4－二醇衍生物

1999
- 1999-02-11 CO CO99008188A patent/CO4990969A1/es unknown
- 1999-02-11 PE PE1999000123A patent/PE20000270A1/es not_active Application Discontinuation
- 1999-02-11 AR ARP990100570A patent/AR017457A1/es active IP Right Grant
- 1999-02-12 KR KR1020007008866A patent/KR20010082512A/ko not_active Withdrawn
- 1999-02-12 PL PL99342396A patent/PL342396A1/xx unknown
- 1999-02-12 DE DE69902758T patent/DE69902758T2/de not_active Expired - Fee Related
- 1999-02-12 YU YU50800A patent/YU50800A/sh unknown
- 1999-02-12 DK DK99906229T patent/DK1056759T3/da active
- 1999-02-12 TR TR2000/02355T patent/TR200002355T2/xx unknown
- 1999-02-12 MA MA25462A patent/MA27121A1/fr unknown
- 1999-02-12 SK SK1200-2000A patent/SK12002000A3/sk unknown
- 1999-02-12 EP EP99906229A patent/EP1056759B1/fr not_active Expired - Lifetime
- 1999-02-12 HU HU0100702A patent/HUP0100702A3/hu unknown
- 1999-02-12 AP APAP/P/2000/001881A patent/AP2000001881A0/en unknown
- 1999-02-12 US US09/622,313 patent/US6610665B1/en not_active Expired - Fee Related
- 1999-02-12 AU AU26235/99A patent/AU757156B2/en not_active Ceased
- 1999-02-12 HR HR20000538A patent/HRP20000538A2/hr not_active Application Discontinuation
- 1999-02-12 CA CA002319009A patent/CA2319009A1/fr not_active Abandoned
- 1999-02-12 SV SV1999000016A patent/SV1999000016A/es not_active Application Discontinuation
- 1999-02-12 NZ NZ505812A patent/NZ505812A/en unknown
- 1999-02-12 ES ES99906229T patent/ES2183516T3/es not_active Expired - Lifetime
- 1999-02-12 AT AT99906229T patent/ATE223429T1/de not_active IP Right Cessation
- 1999-02-12 IL IL13740299A patent/IL137402A0/xx unknown
- 1999-02-12 WO PCT/EP1999/000915 patent/WO1999041267A1/fr not_active Ceased
- 1999-02-12 EA EA200000759A patent/EA200000759A1/ru unknown
- 1999-02-12 JP JP2000531459A patent/JP2002503669A/ja active Pending
- 1999-02-12 BR BR9907886-4A patent/BR9907886A/pt not_active IP Right Cessation
- 1999-02-12 PT PT99906229T patent/PT1056759E/pt unknown
- 1999-02-12 EE EEP200000358A patent/EE200000358A/xx unknown
2000
- 2000-07-25 IS IS5576A patent/IS5576A/is unknown
- 2000-08-11 NO NO20004045A patent/NO20004045D0/no unknown

Also Published As

Publication number	Publication date
CA2319009A1 (fr)	1999-08-19
ES2183516T3 (es)	2003-03-16
HUP0100702A2 (hu)	2002-01-28
MA27121A1 (fr)	2005-01-03
NO20004045D0 (no)	2000-08-11
EE200000358A (et)	2001-10-15
HUP0100702A3 (en)	2003-01-28
KR20010082512A (ko)	2001-08-30
SK12002000A3 (sk)	2001-07-10
AR017457A1 (es)	2001-09-05
SV1999000016A (es)	1999-10-27
EA200000759A1 (ru)	2001-04-23
PL342396A1 (en)	2001-06-04
EP1056759B1 (fr)	2002-09-04
AU757156B2 (en)	2003-02-06
AP2000001881A0 (en)	2000-09-30
BR9907886A (pt)	2000-10-17
EP1056759A1 (fr)	2000-12-06
CO4990969A1 (es)	2000-12-26
NZ505812A (en)	2002-03-01
JP2002503669A (ja)	2002-02-05
IS5576A (is)	2000-07-25
DK1056759T3 (da)	2003-01-06
PT1056759E (pt)	2003-01-31
ATE223429T1 (de)	2002-09-15
YU50800A (sh)	2003-04-30
AU2623599A (en)	1999-08-30
HK1032062A1 (en)	2001-07-06
US6610665B1 (en)	2003-08-26
DE69902758T2 (de)	2003-05-15
IL137402A0 (en)	2001-07-24
TR200002355T2 (tr)	2000-11-21
DE69902758D1 (de)	2002-10-10
HRP20000538A2 (en)	2000-12-31
WO1999041267A1 (fr)	1999-08-19
PE20000270A1 (es)	2000-05-20

Publication	Publication Date	Title
ATE226957T1 (de)	2002-11-15	2-(purin-9-yl)-tetrahydrofuran-3,4-diol-derivat
NO20006548D0 (no)	2000-12-21	2-(purin-9-yl)-tetrahydrofuran-3,4-diolderivater
ATE223429T1 (de)	2002-09-15	2-(purin-9-yl)-tetrahydrofuran-3,4-diol- derivative
IS5774A (is)	2000-12-15	2-(púrín-9-ýl)-tetrahýdrófúran-3,4-díól afleiður
NO993114D0 (no)	1999-06-23	2-(purin-9-yl)-tetrahydrofuran-3,4-diolderivater
SI1056759T1 (en)	2003-04-30	2-(purin-9-yl) -tetrahydrofuran-3, 4-diol derivatives
ZA99689B (en)	2000-07-28	2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives.
ZA991154B (en)	2000-08-14	2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives.
HK1033760A (en)	2001-09-21	2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
ZA9711535B (en)	1999-06-22	2-(Purin-9-yl)-tetrahydrofuran-3,4-diol derivatives